Nicholas Agard | Scientist
Genentech

Nicholas Agard, Scientist, Genentech

Nicholas Agard is a Senior Principal Scientist in the Department of Antibody Engineering at Genentech Inc.  Nicholas received his Ph D. at UC Berkeley, followed by Postdoctoral research at UCSF.  Prior to Genentech, he was a Scientist at Codexis Inc. engineering therapeutic enzymes. He is an author of more than 30 papers and inventor on more than 45 issued patents including grants for three molecules currently in clinical trials.  His current research focuses on advancing new antibody formats and conjugates to develop the next generation of antibody therapeutics.   

Appearances:



Festival of Biologics Day 2 @ 17:20

Direct Tie2 agonists promote vascular stability for the intravitreal treatment of diabetic macular edema

Inhibition of Ang-2, resulting in Tie2 activation, is a clinically validated approach for the treatment of diabetic macular edema.  Here we describe the discovery and optimization of a hexavalent direct Tie2 agonist and its physiological impacts in both mice and cynomolgus monkeys.   We show the molecule resolves vascular leak in response to multiple inflammatory stimuli, including stimuli not addressable by approved agents, and that it has exposure and stability consistent with infrequent intravitreal administration.

last published: 31/Jan/23 09:55 GMT
last published: 31/Jan/23 09:55 GMT

back to speakers